NZ576467A - Smoothened polypeptides and methods of use - Google Patents

Smoothened polypeptides and methods of use

Info

Publication number
NZ576467A
NZ576467A NZ576467A NZ57646707A NZ576467A NZ 576467 A NZ576467 A NZ 576467A NZ 576467 A NZ576467 A NZ 576467A NZ 57646707 A NZ57646707 A NZ 57646707A NZ 576467 A NZ576467 A NZ 576467A
Authority
NZ
New Zealand
Prior art keywords
methods
smoothened
disclosed
polypeptides
smoothened polypeptides
Prior art date
Application number
NZ576467A
Other languages
English (en)
Inventor
Nadya Tarasova
Michael Dean
Hong Lou
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Publication of NZ576467A publication Critical patent/NZ576467A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ576467A 2006-10-31 2007-10-30 Smoothened polypeptides and methods of use NZ576467A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85542206P 2006-10-31 2006-10-31
PCT/US2007/083027 WO2008070357A2 (en) 2006-10-31 2007-10-30 Smoothened polypeptides and methods of use

Publications (1)

Publication Number Publication Date
NZ576467A true NZ576467A (en) 2012-03-30

Family

ID=39492945

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ576467A NZ576467A (en) 2006-10-31 2007-10-30 Smoothened polypeptides and methods of use

Country Status (13)

Country Link
US (3) US8198402B2 (enExample)
EP (2) EP2078036A2 (enExample)
JP (3) JP5399255B2 (enExample)
KR (1) KR101563010B1 (enExample)
CN (2) CN101616931B (enExample)
AU (1) AU2007329678A1 (enExample)
CA (1) CA2667821A1 (enExample)
MY (2) MY181496A (enExample)
NZ (1) NZ576467A (enExample)
PH (1) PH12013502425A1 (enExample)
SG (2) SG178743A1 (enExample)
WO (1) WO2008070357A2 (enExample)
ZA (1) ZA200902894B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008070357A2 (en) * 2006-10-31 2008-06-12 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Smoothened polypeptides and methods of use
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
CN104059124A (zh) 2007-12-27 2014-09-24 无限药品股份有限公司 立体选择性还原的方法
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
US20090181997A1 (en) * 2007-12-27 2009-07-16 Grayzel David Therapeutic cancer treatments
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
JP6141015B2 (ja) 2009-08-05 2017-06-07 インフィニティ ファーマスーティカルズ、インク． シクロパミン類似体の酵素によるアミノ基転移
US20110183948A1 (en) * 2010-01-15 2011-07-28 Infinity Pharmaceuticals, Inc. Treatment of fibrotic conditions using hedgehog inhibitors
AU2011255218B2 (en) 2010-05-21 2015-03-12 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US9376447B2 (en) 2010-09-14 2016-06-28 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
AU2012205669B2 (en) 2011-01-10 2015-08-20 Infinity Pharmaceuticals Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
JP6027610B2 (ja) 2011-07-19 2016-11-16 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環式化合物及びその使用
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2751093A1 (en) 2011-08-29 2014-07-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR102229478B1 (ko) 2012-11-01 2021-03-18 인피니티 파마슈티칼스, 인코포레이티드 Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료
EP2925363A4 (en) 2012-11-29 2016-11-09 Strasspharma Llc METHOD FOR MODULATING FOLLICLE-STIMULATING HORMONACTIVITY
US20160024051A1 (en) 2013-03-15 2016-01-28 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
ES2834638T3 (es) 2013-05-30 2021-06-18 Infinity Pharmaceuticals Inc Tratamiento de cánceres usando moduladores de isoforma de PI3 cinasa
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20160685A1 (es) 2013-10-04 2016-07-23 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
WO2015061204A1 (en) 2013-10-21 2015-04-30 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG10201808053XA (en) 2014-03-19 2018-10-30 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
KR101723649B1 (ko) * 2014-10-23 2017-04-06 서울대학교산학협력단 신규한 펩티드 화합물, 이의 생산 방법, 및 이의 용도
HRP20251395T1 (hr) 2015-06-04 2026-02-13 Sol-Gel Technologies Ltd. Topikalne formulacije za isporuku spojeva inhibitora hedgehog signalnog puta i njihova uporaba
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US20170231968A1 (en) 2016-02-11 2017-08-17 PellePharm, Inc. Method for relief of and treatment of pruritus
JP6889432B2 (ja) * 2016-04-28 2021-06-18 学校法人甲南学園 樹脂固定ペプチド
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX391135B (es) 2016-06-24 2025-03-21 Infinity Pharmaceuticals Inc Terapias de combinacion.
IL268771B2 (en) * 2017-02-19 2024-06-01 Nat Inst Biotechnology Negev Ltd Peptide kinase inhibitors and methods of using them
CN108644311B (zh) * 2018-05-22 2019-09-06 东北大学 一种基于硬化立方刚度吸振器实现方法及吸振器
US12605387B2 (en) 2020-07-24 2026-04-21 Secura Bio, Inc. Treatment of cancers using PI3 kinase isoform modulators

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) * 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
IN165717B (enExample) 1986-08-07 1989-12-23 Battelle Memorial Institute
JP3266311B2 (ja) 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
AU8380898A (en) * 1997-07-01 1999-01-25 Ingham, Philip W Vertebrate smoothened gene, gene products, and uses related thereto
IL125608A0 (en) * 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
US6683192B2 (en) * 2000-03-30 2004-01-27 Curis, Inc. Small organic molecule regulators of cell proliferation
EP2348047A1 (en) * 2000-04-21 2011-07-27 New England Medical Center G protein coupled receptor (GPCR) agonists and antagonists and methods of activating and inhibiting GPCR using the same
EP2862570A1 (en) * 2001-07-02 2015-04-22 Sinan Tas Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
NZ530580A (en) * 2001-07-27 2007-02-23 Curis Inc Mediators of hedgehog signaling pathways, compositions and uses related thereto
WO2004111636A2 (en) * 2003-06-17 2004-12-23 Vib Vzw Peptide combos and their uses
AU2005304963C1 (en) * 2004-11-04 2011-01-06 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of use
US8088976B2 (en) * 2005-02-24 2012-01-03 Monsanto Technology Llc Methods for genetic control of plant pest infestation and compositions thereof
WO2007134272A2 (en) * 2006-05-12 2007-11-22 Janssen Pharmaceutica N.V. Humanized models via targeted mtagenesis with zinc finger nuclease
WO2008070357A2 (en) * 2006-10-31 2008-06-12 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Smoothened polypeptides and methods of use

Also Published As

Publication number Publication date
EP2431388A1 (en) 2012-03-21
MY149170A (en) 2013-07-31
US20130316957A1 (en) 2013-11-28
CN101616931A (zh) 2009-12-30
JP2015180630A (ja) 2015-10-15
WO2008070357A3 (en) 2009-02-26
US8546524B2 (en) 2013-10-01
SG178743A1 (en) 2012-03-29
US8198402B2 (en) 2012-06-12
WO2008070357A2 (en) 2008-06-12
US20120282196A1 (en) 2012-11-08
JP2010508305A (ja) 2010-03-18
CN103435694A (zh) 2013-12-11
SG175691A1 (en) 2011-11-28
KR20090084839A (ko) 2009-08-05
KR101563010B1 (ko) 2015-10-26
WO2008070357A9 (en) 2008-08-14
EP2078036A2 (en) 2009-07-15
JP5739484B2 (ja) 2015-06-24
PH12013502425B1 (en) 2014-10-27
PH12013502425A1 (en) 2014-10-27
CN101616931B (zh) 2013-08-21
HK1137031A1 (en) 2010-07-16
AU2007329678A1 (en) 2008-06-12
US20100093625A1 (en) 2010-04-15
JP5399255B2 (ja) 2014-01-29
CA2667821A1 (en) 2008-06-12
JP2013255500A (ja) 2013-12-26
MY181496A (en) 2020-12-23
ZA200902894B (en) 2010-04-28

Similar Documents

Publication Publication Date Title
PH12013502425B1 (en) Smoothened polypeptides and methods of use
BRPI0519170A8 (pt) formulações de hormônio de crescimento humano que compreendem um aminoácido não naturalmente codificado
PT1991680E (pt) Sistema para a expressão de componentes ortogonais de tradução em células hospedeiras eubacterianas
NZ599792A (en) Immunomodulatory polypeptides derived from il- 2 and their use thereof in the therapeutic of cancer and chronic infections
IN2012DN02981A (enExample)
AU2007325952A8 (en) Cell-free synthesis of proteins containing unnatural amino acids
WO2005049073A3 (en) Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
NZ534919A (en) Bioactive keratin peptides
GB2429207A9 (en) Modified human interferon polypeptides and their uses
WO2006051110A3 (en) Stable formulations of insulinoptropic peptides
MXPA06003474A (es) Agonistas de receptores de melanocortina.
ATE551048T1 (de) Proteinhydrolysate enthaltende kosmetische zusammensetzungen
WO2003070892A3 (en) Inhibitors of rgs proteins
MX2020006822A (es) Proteinas de fusion de anticuerpo de un solo dominio-citosina desaminasa.
WO2011156453A3 (en) Therapeutic peptides
WO2009064366A3 (en) Methods and compositions for protein labeling using lipoic acid ligases
ATE549353T1 (de) Aktive varianten des il-18 bindenden proteins und dessen medizinische verwendungen
BRPI0707420A8 (pt) composições contendo peptídeos com aminoácidos e métodos não naturais do uso
WO2008078167A3 (en) Consensus peptide
WO2004016741A3 (en) Prenylation inhibitors containing dimethyl-cyclobutane and methods of their synthesis and use
WO2004113386A3 (en) Modified hirudin proteins and t-cell epitopes in hirudin
BG66517B1 (bg) Супресор на ендогенния човешки гама - интерферон
ATE484290T1 (de) Peptid mit antitumoraler wirkung
ATE510009T1 (de) Förderung der peroxisomalenkatalasefunktion in zellen

Legal Events

Date Code Title Description
PSEA Patent sealed
LAPS Patent lapsed